Low granulocytes, a condition doctors call granulocytopenia or more commonly neutropenia, means your body has fewer infection-fighting white blood cells than it needs. Since neutrophils make up the vast majority of granulocytes, most clinical concern centers on neutrophil counts falling below 1,500 cells per microliter of blood. The causes range from chemotherapy and prescription drugs to inherited genetic mutations, and the consequences depend heavily on how low the count drops and how long it stays there.
What Granulocytes Do and Why the Numbers Matter
Granulocytes are a family of white blood cells named for the tiny granules visible inside them under a microscope. The family includes neutrophils, eosinophils, and basophils, but neutrophils dominate. They are the immune system’s rapid responders, rushing to sites of bacterial and fungal invasion to engulf and kill pathogens. They are also remarkably short-lived, circulating in the blood for only about six to eight hours before being replaced, which means your bone marrow produces billions of fresh neutrophils every single day just to maintain a steady supply.1PubMed Central. Neutrophil kinetics in health and disease That rapid turnover is part of why neutrophil counts are so sensitive to anything that disrupts bone marrow function.
When neutrophil counts dip below 1,500 per microliter, you have mild neutropenia. Below 1,000 is moderate. Below 500 is severe, and at that level the risk of dangerous infections climbs steeply. The most critical threshold in clinical practice is below 100 cells per microliter, sometimes called profound neutropenia, which leaves you essentially defenseless against bacteria and fungi.
Medications That Lower Granulocytes
Drug-induced neutropenia is one of the most common reasons for an unexpectedly low granulocyte count. Chemotherapy drugs are the obvious culprit, since they target rapidly dividing cells and the bone marrow’s neutrophil factory fits that description perfectly. But plenty of non-cancer medications can do it too, sometimes unpredictably.
The most studied example is clozapine, an antipsychotic used for treatment-resistant schizophrenia. Clozapine can cause severe neutropenia or outright agranulocytosis, where neutrophils nearly vanish. Research has shown that the drug gets converted inside neutrophils and their bone marrow precursors into a reactive metabolite, likely a nitrenium ion, which binds to neutrophil proteins and can either disrupt the cell directly or trigger an immune reaction against the body’s own neutrophils.2PubMed. Mechanism of clozapine-induced agranulocytosis: current status of research and implications for drug development More recent work has tied the enzyme myeloperoxidase to this process, showing that blocking myeloperoxidase activity in animal models dampened the inflammatory cascade clozapine triggers, including neutrophil mobilization from the bone marrow and the release of inflammatory signals from the liver, spleen, and bone marrow.3PubMed Central. The Role of Myeloperoxidase in Clozapine-Induced Inflammation: A Mechanistic Update for Idiosyncratic Drug-Induced Agranulocytosis Because of this risk, patients on clozapine undergo regular blood monitoring for the duration of treatment.
Beyond clozapine, other medications known to occasionally cause neutropenia include certain antibiotics, anti-thyroid drugs, anti-seizure medications, and some anti-inflammatory drugs. The reaction is often idiosyncratic, meaning it is not predictable from the dose and does not happen to everyone. If a new medication coincides with a drop in your granulocyte count, stopping the drug is usually the first step, and counts typically recover within one to three weeks.
Infections and Autoimmune Causes
Viral infections are a surprisingly common trigger for temporary neutropenia, particularly in children. Many garden-variety viruses can suppress bone marrow production for days to weeks. SARS-CoV-2 has also been linked to neutropenia, particularly in patients with severe COVID-19, though it is considered a relatively uncommon complication of the infection.4Elsevier / The American Journal of the Medical Sciences. Neutropenia and SARS-CoV-2 infection, A review of the literature HIV, hepatitis B and C, and Epstein-Barr virus can all cause longer-lasting drops in neutrophil counts through direct bone marrow suppression or immune-mediated destruction.
In autoimmune neutropenia, your immune system manufactures antibodies that target your own neutrophils. These anti-neutrophil antibodies most often bind to a receptor on the neutrophil surface, causing both a drop in numbers and impaired function, which together raise the risk of infection.5PubMed Central. Primary and secondary autoimmune neutropenia In young children, autoimmune neutropenia tends to resolve on its own within months to a couple of years. In adults, it is more often secondary to another autoimmune condition like lupus or rheumatoid arthritis, and managing the underlying disease is part of the treatment strategy.
Inherited and Congenital Neutropenia
Some people are born with genetic mutations that impair neutrophil production. The most well-known forms are severe congenital neutropenia and cyclic neutropenia, both of which are frequently caused by mutations in the ELANE gene, which encodes a protein called neutrophil elastase.6PubMed Central. ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology In severe congenital neutropenia, the bone marrow essentially gets stuck partway through producing mature neutrophils. Cyclic neutropenia follows a different pattern, with neutrophil counts dropping to dangerously low levels roughly every three weeks before recovering, then dropping again.
Other genes are involved too. Mutations in HAX1, CXCR4, and SBDS each produce distinct clinical pictures, with varying degrees of neutropenia and different associated features.7Blood Advances. Impact of different genetic mutations on granulocyte development and G-CSF responsiveness in congenital neutropenia These conditions are rare individually, but collectively they represent an important subset of patients who live with chronically low granulocyte counts from birth.
Nutritional Deficiencies
Your bone marrow needs raw materials to build neutrophils. Deficiencies in vitamin B12, folate, and copper can all result in low granulocyte counts. Copper deficiency in particular produces a recognizable triad of anemia, low white blood cells, and nerve damage, because copper serves as a cofactor in the enzymatic processes involved in cell division and protein synthesis throughout the bone marrow.8PubMed Central. Copper deficiency, a new triad: anemia, leucopenia, and myeloneuropathy Copper deficiency is not common in people eating a typical diet, but it can develop after gastric bypass surgery, in people taking high doses of zinc supplements (zinc competes with copper for absorption), or in individuals with malabsorption conditions. The good news is that neutropenia from nutritional causes usually reverses once the deficiency is corrected.
Benign Ethnic Neutropenia
Millions of people walk around with neutrophil counts that would be flagged as low on a standard lab reference range, yet face no increased risk of infection. This phenomenon, called benign ethnic neutropenia, is especially common in people of African descent. The cause traces to a genetic variant in the Duffy antigen receptor gene (DARC). A specific change in this gene abolishes the Duffy receptor on red blood cells, which alters how chemokines, the signaling molecules that recruit neutrophils, circulate in the bloodstream.9PLoS Genetics. Reduced Neutrophil Count in People of African Descent Is Due To a Regulatory Variant in the Duffy Antigen Receptor for Chemokines Gene
The important detail is that these individuals are not actually short on neutrophils. Research indicates that their neutrophils are not being underproduced but rather are leaving the bloodstream and moving into tissues, particularly the spleen.10Human Molecular Genetics. The Duffy-null genotype and risk of infection Studies in people with the Duffy-null genotype have shown that their neutrophils appear activated and egress from the blood to reside in other compartments, which explains the low circulating count without any actual immune compromise.11PLoS ONE. Analyses of genome wide association data, cytokines, and gene expression in African-Americans with benign ethnic neutropenia This matters clinically because a person with benign ethnic neutropenia should not be subjected to unnecessary bone marrow biopsies or withheld from chemotherapy regimens based on reference ranges that were established in predominantly European populations.
Signs and Symptoms
Low granulocytes by themselves do not cause symptoms. You will not feel your neutrophil count dropping. What you feel are the consequences: infections that take hold because there are not enough neutrophils to fight them off. The mouth is one of the first places trouble shows up. Oral ulcers are strongly associated with neutropenia, and in cyclic neutropenia, roughly nine out of ten patients develop recurring mouth sores that appear right after neutrophil counts hit their lowest point, along with fever, fatigue, and swollen lymph nodes in the neck.12PubMed Central. Association of neutrophil defects with oral ulcers but undetermined role of neutrophils in recurrent aphthous stomatitis
The classic presentation of cyclic neutropenia involves repetitive episodes of fever, painful mouth ulcers, and bacterial infections that cycle in and out over roughly three-week intervals.13PubMed. Cyclic neutropenia In non-cyclic forms of severe neutropenia, the pattern is less predictable, but the symptoms are similar: recurring skin infections, gum disease, abscesses, pneumonia, and sometimes bloodstream infections. The milder the neutropenia, the less frequent and less severe these infections tend to be. Many people with mild neutropenia never notice anything at all.
When Low Granulocytes Become an Emergency
Febrile neutropenia, a fever in someone with severely depressed neutrophil counts, is treated as a medical emergency. In cancer patients who have recently received chemotherapy, a fever may be the only visible sign that an infection is developing, because the inflammatory response that normally produces redness, swelling, and pus depends on neutrophils that are not there.14PubMed Central. Management and Preventive Measures for Febrile Neutropenia This means the usual clues, such as a clearly infected wound or obvious pneumonia on a chest X-ray, may be muted or absent. Standard practice calls for starting antibiotics immediately, before culture results come back, because waiting even a few hours can be dangerous.
Guidelines from major oncology and infectious disease societies recommend that patients with febrile neutropenia be stratified by risk. Low-risk patients, those expected to have short periods of neutropenia with no serious co-existing illnesses, may be treated with oral antibiotics and sent home. High-risk patients, especially those with profound neutropenia expected to last more than a week, require hospitalization and intravenous antibiotics.15PubMed. Emergency Department Management of Patients With Febrile Neutropenia: Guideline Concordant or Overly Aggressive?
How Low Granulocytes Are Diagnosed
A standard complete blood count with differential is usually the starting point. If the count comes back low, the next steps depend on the suspected cause. A blood smear lets a lab technician examine the shape and maturity of the cells present, looking for immature forms or abnormal cells that might point toward a bone marrow problem. Bone marrow biopsy is reserved for cases of severe or unexplained neutropenia. In congenital forms, the marrow typically shows a characteristic “arrest” where neutrophil precursors get stuck at an early developmental stage and never mature. In drug-induced or autoimmune neutropenia, the marrow often looks normal or even hyperactive, because the bone marrow is trying to compensate for the destruction happening in the bloodstream.16PubMed Central. Diagnosis and management of neutropenia
When congenital neutropenia is suspected, genetic testing can confirm mutations in ELANE, HAX1, and other relevant genes. For autoimmune neutropenia, antibody testing using specialized assays can detect the presence of anti-neutrophil antibodies, though these tests are not available at every lab and can sometimes produce false negatives.16PubMed Central. Diagnosis and management of neutropenia
Treatment With G-CSF
The workhorse treatment for chronic and congenital neutropenia is granulocyte colony-stimulating factor, or G-CSF, a drug that stimulates the bone marrow to produce more neutrophils. In clinical trials, G-CSF raised neutrophil counts and reduced infections in the vast majority of patients with severe congenital and cyclic neutropenia. Out of 44 patients with severe congenital neutropenia, 40 showed a sustained improvement in counts, and the frequency of serious infections dropped along with the need for intravenous antibiotics.17PubMed. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias G-CSF is not without side effects. Long-term use has been associated with bone thinning, enlarged spleen, and in a small number of cases, the development of myelodysplastic syndrome or leukemia, which is why patients on chronic G-CSF need ongoing monitoring.
For chemotherapy patients, G-CSF is used preventively to shorten the period of dangerously low counts after each treatment cycle. Biosimilar versions of filgrastim, the original G-CSF product, have been studied in large pooled analyses and shown to be just as effective as the brand-name drug at preventing febrile neutropenia, with similar safety profiles and costs roughly 15 to 32 percent lower.18Annals of Medicine and Surgery. G-CSF biosimilars vs. originator filgrastim for febrile neutropenia prophylaxis: systematic review of cost-effectiveness, safety, and clinical outcomes The timing of the injection matters. Research on chemotherapy patients found that giving G-CSF the day after chemo, rather than the same day, resulted in higher neutrophil counts at the nadir, the lowest dip.19PubMed Central. Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy
Preventive Antibiotics and Antifungals
When neutropenia is expected to be severe and prolonged, such as after intensive chemotherapy for blood cancers, guidelines from ASCO and the Infectious Diseases Society of America recommend preventive antibacterial and antifungal medications. The threshold for this recommendation is a neutrophil count below 100 per microliter expected to last longer than seven days.20Journal of Oncology Practice. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary The antifungal piece is especially important for patients with blood cancers, who face a higher risk of invasive fungal infections during prolonged neutropenia.21Journal of Antimicrobial Chemotherapy. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review
Stem Cell Transplant for Refractory Cases
For patients with severe congenital neutropenia who do not respond adequately to G-CSF, or who require very high doses, stem cell transplant is the definitive treatment. These patients face the highest risk of both life-threatening infections and malignant transformation, particularly if they develop mutations in the G-CSF receptor gene. Published outcomes show that transplant is highly successful in patients who have not yet developed leukemia, which is a strong argument for proceeding to transplant before malignant changes appear rather than waiting.22PubMed Central. Hematopoietic stem cell transplantation for severe congenital neutropenia Transplant carries its own serious risks, including graft failure and graft-versus-host disease, so it is generally reserved for patients whose disease cannot be safely managed with G-CSF alone.
The Neutropenic Diet Myth
For decades, hospitals put neutropenic patients on restricted “neutropenic diets” that avoided raw fruits, raw vegetables, and certain other fresh foods under the theory that uncooked produce carried bacteria that could cause dangerous infections in immune-compromised people. The evidence has not supported this practice. A meta-analysis found that the neutropenic diet did not reduce the incidence of infection or mortality compared with a standard hospital diet.23PubMed Central. Neutropenic Diet Cannot Reduce the Risk of Infection and Mortality in Oncology Patients With Neutropenia
A broader scoping review reached the same conclusion and added that the restrictive diet may actually cause harm by contributing to malnutrition, decreasing mealtime satisfaction, and reducing quality of life, particularly in children. Despite this evidence, more than half of hospitals in Europe and China still use neutropenic diet protocols.24PubMed Central. The neutropenic diet and its impacts on clinical, nutritional, and lifestyle outcomes for people with cancer: a scoping review If you or a family member is placed on a neutropenic diet during treatment, it is worth discussing the evidence with the care team. Good food safety practices like thorough washing and proper refrigeration are reasonable; eliminating entire food groups is not well supported.
Living With Chronic Neutropenia
Beyond the infection risk, chronic severe neutropenia takes a real toll on daily life. Patients with chronic neutropenia conditions report significantly lower quality of life compared to healthy individuals, with particular impact on physical functioning, fatigue, cognitive functioning, and pain.25PubMed. Quality of life and patient-reported outcomes in chronic severe neutropenia conditions Adults tend to be hit harder than children. One survey found that adults with chronic neutropenia scored substantially below healthy population norms on overall quality of life measures, while children’s scores, though lower, were closer to the benchmark.26Blood. Quality of Life and Patient Reported Outcomes in Severe Chronic Neutropenia
Some of this burden comes from the disease itself: recurring infections, mouth sores, fatigue, and the physical toll of chronic G-CSF injections. But a significant part comes from the anxiety and lifestyle disruption of living with an unpredictable immune system. People with chronic neutropenia often modify their social behavior, avoid crowded places during periods of low counts, and live with the knowledge that a routine cold could escalate. Support from hematology teams who understand these quality-of-life dimensions, not just the lab numbers, makes a measurable difference.
When Low Eosinophils or Basophils Show Up
Although neutrophils dominate the clinical conversation about low granulocytes, eosinophils and basophils are technically granulocytes too. Low eosinophil counts (eosinopenia) can appear during acute stress, corticosteroid use, or severe infections, but the practical impact appears minimal. Studies of people who lack eosinophils entirely, whether due to immune deficiency or treatment with anti-eosinophil therapies, have not found any distinctive health problems resulting from the absence. Patients treated with the anti-eosinophil antibody mepolizumab for as long as six years showed no characteristic set of adverse effects from eosinophil depletion.27PubMed Central. The consequences of not having eosinophils Low basophil counts are similarly unremarkable in clinical practice. Basophils make up less than one percent of circulating white blood cells, and isolated low basophil counts are almost never investigated or treated.
Neutrophil Recovery After Chemotherapy
If you are going through chemotherapy, the timeline of your neutrophil nadir and recovery matters for treatment planning. In one study of patients receiving induction chemotherapy for acute lymphoblastic leukemia, the median neutrophil count bottomed out around day 17, with partial recovery by about day 23 and complete recovery by day 27.28PubMed Central. Peripheral Blood Neutrophil Nadir and Time to Platelet Recovery during Induction Chemotherapy The timing of that nadir turned out to carry prognostic weight: patients whose counts bottomed out later than day 15 had higher odds of treatment-resistant disease. Modeling studies have shown that frequent monitoring of neutrophil counts can predict the timing of recovery about six days in advance, giving clinicians a window to plan the next chemotherapy cycle or adjust supportive care.29PubMed Central. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
The practical takeaway: if you are tracking your blood counts during chemotherapy, expect the lowest point roughly two to three weeks after treatment, and know that your medical team is watching the trajectory of recovery closely because it informs both your infection risk and your response to therapy.